ArticleVirchows Archiv : an international journal of pathology2026
PTEN status, tumor immune microenvironment, and survival in colorectal cancer.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interleukin-8 in health and disease.Molecular biomedicine · 2026Review
- Prognostic value of the C-reactive protein-albumin-lymphocyte index versus traditional inflammatory markers after radical resection of colorectal cancer: a retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Phosphatase and tensin homolog (PTEN) is a tumor suppressor involved in cell proliferation, DNA repair, apoptosis, and cell cycle regulation. Its loss has been linked to worse prognosis and poor immune therapy response in several cancers, but findings in colorectal cancer (CRC) have been inconsistent. This study aims to evaluate the prognostic value of PTEN expression and its relationship with the tumor immune microenvironment in two large CRC cohorts (combined N = 2303). PTEN expression was assessed by immunohistochemistry and categorized as intact, reduced, or lost. Additionally, three multiplex immunohistochemistry assays were used to assess immune cell composition and expression of immunosuppressive markers within the tumor environment. PTEN loss was observed in 12% of tumors in cohort 1 and 11% in cohort 2. PTEN expression status showed no significant prognostic value. For CRC-specific mortality, the multivariable HR for PTEN loss (vs. intact expression) was 1.19 (95% CI 0.88-1.61) in cohort 1 and 0.85 (95% CI 0.55-1.31) in cohort 2. PTEN loss was associated with BRAF mutations and mismatch repair (MMR) deficiency in both cohorts, but was not independently associated with tumor immune cell composition or expression of PD-L1, PD-1, IDO, and ARG1. In conclusion, PTEN immunohistochemistry lacked prognostic value in CRC and did not reflect the tumor immune landscape. These findings suggest that PTEN immunohistochemistry alone may have limited clinical utility as a biomarker in CRC, highlighting the need for complementary genomic profiling in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.